Bendamustine in combination with thalidomide and prednisone in patients with refractory or relapsed multiple myeloma. preliminary results of a phase I clinical trial

被引：0
|
作者：
Pönisch, W
Rozanski, M
Leiblein, S
Goldschmidt, H
Wegner, A
Niederwieser, D
机构：
[1] Univ Leipzig, Dept Haematol Oncol, D-7010 Leipzig, Germany
[2] Ribosepharm GmbH, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
584
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [41] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Wolfram Pönisch
    Malvina Bourgeois
    Barbara Moll
    Simone Heyn
    Nadja Jäkel
    Ina Wagner
    Robert Rohrberg
    Hans-Jürgen Hurtz
    Marion Schmalfeld
    Michael Aßmann
    Thomas Edelmann
    Martin Mohren
    Franz Albert Hoffmann
    Cornelia Becker
    Andreas Schwarzer
    Uta Schönfelder
    Thomas Zehrfeld
    Gerald Hensel
    Kerstin Löschcke
    Rainer Krahl
    Haifa Al Ali
    Dietger Niederwieser
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 499 - 508
  • [42] Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study
    Facon, Thierry
    Leleu, Xavier
    Stewart, A. Keith
    Spencer, Andrew
    Rowlings, Philip
    Hulin, Cyrille
    Attal, Michel
    Garzon, Felix
    Bleickardt, Eric
    Gialelis, Konstantina
    Tuozzoli, Doreen
    Derreumaux, Dorninique
    Sonneveld, Pieter
    BLOOD, 2009, 114 (22) : 744 - 745
  • [43] Phase VII dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Rizzieri, David
    Diehl, Louis F.
    Beaven, Anne W.
    Li, Zhiguo
    Garrett, Anderson
    McIntyre, Jackie
    Long, Gwynn Douglas
    Chao, Nelson Jen An
    Gasparetto, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy:: results of a Phase I clinical trial
    Poenisch, Wolfram
    Rozanski, Marta
    Goldschmidt, Hartmut
    Hoffmann, Franz Albert
    Boldt, Thomas
    Schwarzer, Andreas
    Ritter, Ute
    Rohrberg, Robert
    Schwalbe, Elke
    Uhlig, Jens
    Zehrfeld, Thomas
    Schirmer, Veronika
    Haas, Antje
    Kreibich, Ute
    Niederwieser, Dietger
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (02) : 191 - 200
  • [46] Treatment with bendamustine, thalidomide and prednisolone (BPT) in patients with refractory or relapsed multiple myeloma after autologous stem cell transplantation or conventional chemotherapy: Results of a phase I clinical trial.
    Poenisch, Wolfram
    Rozanski, Marta
    Goldschmidt, Hartmut
    Hoffmann, Franz-Albert
    Boldt, Thomas
    Schwarzer, Andreas
    Ruffert, Ute
    Rohrberg, Robert
    Schwalbe, Elke
    Uhlig, Jens
    Zehrfeld, Thomas
    Schirmer, Veronika
    Haas, Amje
    Kreibich, Ute
    Niederwieser, Dietger
    BLOOD, 2006, 108 (11) : 1018A - 1018A
  • [47] Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
    Palumbo, A
    Avonto, I
    Bruno, B
    Ambrosini, MT
    Bringhen, S
    Cavallo, F
    Falco, P
    Boccadoro, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (04) : 273 - 277
  • [48] Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Vij, Ravi
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Facon, Thierry
    Pegourie, Brigitte
    Benboubker, Lotfi
    Gasparetto, Cristina
    Amiot, Martine
    Moreau, Philippe
    Diehl, Susan
    Alzate, Stefanie
    Ross, Jeremy A.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh K.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] A phase I/II trial evaluating the combination of arsenic trioxide, bortezomib and ascorbic acid for patients with relapsed or refractory multiple myeloma.
    Berenson, J
    Matous, J
    Ferretti, D
    Swift, R
    Mapes, R
    Morrison, B
    Yeh, H
    Bevivino, S
    BLOOD, 2005, 106 (11) : 721A - 721A
  • [50] Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma.
    Caravita, T
    Siniscalchi, A
    Niscola, P
    Santinelli, S
    Buccisano, F
    Montanaro, M
    De Fabritiis, P
    Amadori, S
    BLOOD, 2003, 102 (11) : 382B - 383B
12345